Common Variable Immunodeficiency — Research Summary
Printed from RareWays (rareways.com.au) on 27 July 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Molecular investigation of
Tahmasebi Ashtiani Zahra et al. — New microbes and new infections (1 August 2026)
https://pubmed.ncbi.nlm.nih.gov/42238847/
- 2.
Chronic spontaneous urticaria as an autoimmune feature in common variable immunodeficiency.
Korevaar E C A et al. — The journal of allergy and clinical immunology. Global (1 July 2026)
https://pubmed.ncbi.nlm.nih.gov/42256028/
- 3.
Subacute large bowel obstruction as an unusual presentation of selective IgA deficiency.
Forouzanfar Elizabeth et al. — The journal of allergy and clinical immunology. Global (1 July 2026)
https://pubmed.ncbi.nlm.nih.gov/42211874/
- 4.
Common variable immunodeficiency with autoimmune hepatitis.
Wang Chrong-Reen et al. — Journal of the Formosan Medical Association = Taiwan yi zhi (1 July 2026)
https://pubmed.ncbi.nlm.nih.gov/41233244/
- 5.
Clinical Practice Guideline for the diagnosis of Granulomatous-Lymphocytic Interstitial Lung Disease (GLILD) in patients with Common Variable Immunodeficiency Disorders (CVID) - an ERS Clinical Research Collaboration.
Bintalib Heba M et al. — The European respiratory journal (25 June 2026)
https://pubmed.ncbi.nlm.nih.gov/42350065/
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Common Variable Immunodeficiency
Common Variable Immunodeficiency is the most common symptomatic primary antibody deficiency, characterised by low immunoglobulin levels, poor vaccine responses, and increased susceptibility to recurrent infections. It is typically diagnosed in the second or third decade of life. Treatment requires regular immunoglobulin replacement therapy.
Most Recent Research
BACKGROUND: Bartonella infections are emerging zoonotic pathogens, primarily transmitted through arthropod vectors or direct contact with animals. Immunocompromised individuals are at increased risk of developing severe complications. METHODS: In this cross-sectional study, a total of 370 blood samples were collected from immunocompromised individuals including patients with HIV, AIDS, common variable immunodeficiency (CVID), liver and kidney transplant recipients, and a control group in Imam Khomeini Hospital in Tehran from May 2024 to February 2025. RESULT: Overall, Bartonella spp. were detected in 7 out of 370 participants (1.89%). All positive cases were among HIV+ (2.8) and AIDS patients (3.9%). Phylogenetic analysis identified all isolates as Bartonella quintana. Univariate analysis suggested that a history of drug abuse and flea infestation seemed to be associated with infection, but due to the rarity of events, multivariate penalized logistic regression did not confirm these as independent risk factors. Cautious interpretation is warranted. CONCLUSION: This study provides the first molecular evidence of Bartonella quintana infection among immunocompromised patients in Iran, with a notable prevalence observed in HIV-infected individuals, highlighting the need for increased clinical awareness in this population.
Common Questions
What is Common Variable Immunodeficiency?
Common Variable Immunodeficiency is the most common symptomatic primary antibody deficiency, characterised by low immunoglobulin levels, poor vaccine responses, and increased susceptibility to recurrent infections. It is typically diagnosed in the second or third decade of life. Treatment requires regular immunoglobulin replacement therapy.
How many clinical trials are available for Common Variable Immunodeficiency?
RareWays currently indexes 46 clinical trials for Common Variable Immunodeficiency, of which 7 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Common Variable Immunodeficiency come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Common Variable Immunodeficiency.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.